Cognitive Impairment Disorders Drug Development Pipeline Review, 2018
Summary
This report provides an overview of the pipeline landscape for cognitive impairment disorders. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for cognitive impairment associated with schizophrenia CIAS, dementia, mild cognitive impairment and Alzheimer's disease, and features dormant and discontinued products.
These disorders are associated with impairments in cognitive abilities such as learning, memory and perception. Due to the complex and highly sophisticated nature of the central nervous system CNS, the pathophysiology of these disorders is not well understood and treatment options remain limited. Currently, marketed drugs act by slowing disease progression or treating symptoms.
Worldwide, the burden of cognitive impairment disorders will increase significantly in the coming decades due to aging populations. Consequently, there is a strong need to develop new therapies that effectively treat symptoms and target underlying mechanisms of disease.
Scope
Which companies are the most active within the pipeline for cognitive impairment disorders?
Which pharmaceutical approaches are most prominent at each stage of the pipeline and within each indication?
To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
What are the most important RD milestones and data publications to have happened within this field?
Reasons to buy
Understand the overall pipeline, with an ataglance overview of all products in therapeutic development for each indication
Assess the products in development in granular detail, with an uptodate overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration